Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122048 | 1.00 | CYP19A1 (0.53) | CYP19A1ACHEACEMEN1KMT2A | |
| SCHEMBL600079 | 1.00 | CYP19A1 (0.53) | CYP19A1ACHEACEMEN1KMT2A | |
| SCHEMBL5880416 | 0.85 | ACE (0.67) | CYP19A1ACHEACEMEN1KMT2A | |
| SCHEMBL29666098 | 0.85 | ACE (0.67) | CYP19A1ACHEACEMEN1KMT2A | |
| SCHEMBL677552 | 0.85 | ACE (0.67) | CYP19A1ACHEACEMEN1KMT2A | |
| SCHEMBL26312410 | 0.85 | CYP19A1 (0.57) | CYP19A1ACHEACEMEN1KMT2A | |
| SCHEMBL8243497 | 0.85 | ACE (0.67) | CYP19A1ACHEACEMEN1KMT2A | |
| SCHEMBL16265990 | 0.84 | CYP19A1 (0.56) | CYP19A1ACHEACEMEN1KMT2A | |
| SCHEMBL24380346 | 0.83 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL16750308 | 0.83 | CYP19A1 (0.72) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | CYP19A1 1771/4885ACHE 875/4885ACE 4079/4885 |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | CYP19A1 1771/4885ACHE 875/4885ACE 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.